Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.62 |
| ▸ | CDK2 | P24941 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052313 | 1.00 | CDK1 (0.62) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL2153079 | 0.86 | HDAC6 (0.56) | CYP2C19HSP90AA1HSP90AB1HDAC6HDAC1 | |
| SCHEMBL9388321 | 0.85 | CYP2C19 (0.47) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL7388886 | 0.85 | CCNE1 (0.59) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL4735463 | 0.82 | CDK1 (0.49) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL23885478 | 0.81 | CDK1 (0.44) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL30052639 | 0.81 | CDK1 (0.44) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL8768015 | 0.81 | HSP90AB1 (0.52) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL431825 | 0.80 | CDK1 (0.61) | CDK1CCNB1CCNE1CDK2CYP2C19 | |
| SCHEMBL22300666 | 0.80 | CCNE1 (0.70) | CDK1CCNB1CCNE1CDK2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200292535-A1 | METHOD FOR EVALUATION OF TARGET IN HISTOLOGICAL SAMPLE | DAKO DENMARK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-10648970-B2 | Method for evaluation of target in histological sample | AGILENT TECHNOLOGIES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2646795-B1 | METHODS FOR ANALYZING IMAGES OF SPECIMENS PROCESSED BY A PROGRAMMABLE QUANTITATIVE ASSAY | DAKO DENMARK AS (DK) | 2019-02-20 | — | — | EP | disclosed |
| US-10180426-B2 | Quantification of single target molecules in histological samples | DAKO DENMARK A/S (DK) | 2019-01-15 | — | — | US | disclosed |
| US-9970874-B2 | Methods and systems for analyzing images of specimens processed by a programmable quantitative assay | DAKO DENMARK A/S (DK) | 2018-05-15 | — | — | US | disclosed |
| US-20100240085-A1 | CONJUGATE MOLECULES | DAKO DENMARK APS (DK) | 2010-09-23 | — | — | US | disclosed |
| WO-2010094284-A1 | METHODS AND COMPOUNDS FOR DETECTION OF MOLECULAR TARGETS | DAKO DENMARK A/S (DK) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094283-A1 | CONJUGATE MOLECULES | DAKO DENMARK A/S (DK) | 2010-08-26 | — | — | WO | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1085020-A1 | Synthesis of modified diaminopurines and their incorporation into oligomers | DAKO A/S (DK) | 2001-03-21 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | CDK1 537/4885CCNB1 742/4885CCNE1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.